• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

1.610 UNCHANGED
Delayed Quote Updated: 3:46 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,183
Open 1.610
Bid (Size) 1.550 (100)
Ask (Size) 1.620 (100)
Prev. Close 1.610
Today's Range 1.600 - 1.636
52wk Range 1.370 - 28.44
Shares Outstanding 11,523,716
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
October 14, 2026
Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment 
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
September 24, 2026
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human Testing Trispecifics Combine Three Complementary Cancer-Fighting Functions in... 
From Aptevo Therapeutics
Via ACCESS Newswire

Performance

52-Week Range 94.3% below 52-week high
1.610
1.3752W Low 28.4452W High
1 Week 2.7% below 1-week high
1.571W Low 1.661W High

Aptevo Therapeutics Inc. - Common Stock (APVO) traded between $1.37 and $28.44 over the past 52 weeks and last traded at $1.61, 94.3% below its 52-week high. Over the past week it ranged between $1.57 and $1.66.

Past 12 Months
+0.6%
-14.8%
-63.3%
-66.9%
-82.9%
-94.2%
1W +$0.01
1M -$0.28
3M -$2.78
6M -$3.26
YTD -$7.78
1Y -$25.93

APVO was -94.2% over the past year, -66.9% over six months, -82.9% year to date, +0.6% in the last week.

12 Months vs Market
APVO
-94.2%
DIA
+11.6%
SPY
+13.1%
QQQ
+15.4%
IWM
+11.9%

Over the past 12 months APVO returned -94.2% versus DIA (Dow) +11.6%, SPY (S&P 500) +13.1%, QQQ (Nasdaq 100) +15.4% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 0.08× 3-mo avg
Today 7,183 3-mo avg 91.4K
1W
8.4K
1M
35.9K
3M
91.4K
6M
74.2K
YTD
100.3K
1Y
94.9K

APVO most recently traded 7,183 shares against a 3-month average daily volume of 91.4K.

More News

Read More
The trading volume of these stocks is deviating from the norm in today's session. ↗
September 04, 2026
Via Chartmill
News headline image
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
September 03, 2026
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
August 14, 2026
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
August 13, 2026
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
August 12, 2026
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
July 27, 2026
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
June 30, 2026
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category
June 09, 2026
Via NewMediaWire
News headline image
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
May 28, 2026
Via ACCESS Newswire
News headline image
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
May 27, 2026
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 13, 2026
Via ACCESS Newswire
News headline image
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 06, 2026
Via ACCESS Newswire
News headline image
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment
March 27, 2026
Via NewMediaWire
News headline image
Aptevo Provides State of the Business Report and 2025 Financial Results
March 26, 2026
Via ACCESS Newswire
News headline image
Aptevo to Participate in March 2026 Conferences
March 19, 2026
Via ACCESS Newswire
Gapping stocks in Tuesday's session ↗
March 10, 2026
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
March 10, 2026
Via Chartmill
News headline image
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
March 10, 2026
Via ACCESS Newswire
News headline image
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
February 03, 2026
Via ACCESS Newswire
Friday's pre-market session: top gainers and losers ↗
January 09, 2026
Via Chartmill
News headline image
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
January 09, 2026
Via ACCESS Newswire
News headline image
These stocks are moving in today's session ↗
December 26, 2025
Via Chartmill
News headline image
Top movers in Friday's session ↗
December 26, 2025
Via Chartmill

Frequently Asked Questions

Is Aptevo Therapeutics Inc. - Common Stock publicly traded?
Yes, Aptevo Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Aptevo Therapeutics Inc. - Common Stock trade on?
Aptevo Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aptevo Therapeutics Inc. - Common Stock?
The ticker symbol for Aptevo Therapeutics Inc. - Common Stock is APVO on the Nasdaq Stock Market
What is the current price of Aptevo Therapeutics Inc. - Common Stock?
The current price of Aptevo Therapeutics Inc. - Common Stock is 1.610
When was Aptevo Therapeutics Inc. - Common Stock last traded?
The last trade of Aptevo Therapeutics Inc. - Common Stock was at 10/23/26 03:46 PM ET
What is the market capitalization of Aptevo Therapeutics Inc. - Common Stock?
The market capitalization of Aptevo Therapeutics Inc. - Common Stock is 18.55M
How many shares of Aptevo Therapeutics Inc. - Common Stock are outstanding?
Aptevo Therapeutics Inc. - Common Stock has 19M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap